Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Discovery May Lead to Alzheimer's Treatments

February 11, 2011 7:01 am | News | Comments

Scientists have made a discovery that has the potential for use in the early diagnosis and eventual treatment of plaque-related diseases such as Alzheimer's disease and Type 2 diabetes.

TOPICS:

TB-402 Performs Well in VTE Trial

February 11, 2011 6:51 am | News | Comments

BioInvent International AB and co-development partner ThromboGenics NV have announced positive results of a TB-402 Phase 2 trial, evaluating the product’s efficacy and safety for the prevention of venous thromboembolism after orthopaedic surgery.

TOPICS:

Juvista Fails Late-Stage Trial

February 11, 2011 6:46 am | News | Comments

Renovo Group plc, which develops drugs to reduce scarring, improve wound healing, and enhance tissue regeneration, announces that its first EU Phase 3 trial for Juvista in scar revision surgery (REVISE) did not meet its primary or secondary endpoints.

TOPICS:
Advertisement

Shire Profits Drop On Costs

February 11, 2011 6:42 am | News | Comments

Irish drug developer Shire Plc. said its fourth-quarter profit fell on higher costs, but the results met Wall Street expectations. The company earned $165.1 million, down from $174.3 million.

TOPICS:

Lilly Names New Cancer President

February 11, 2011 6:39 am | News | Comments

Eli Lilly and Co. named company insider Sue Mahony as president of its cancer drug business. The change is effective immediately. Mahony has worked at Eli Lilly for about 10 years, the company said.

TOPICS:

Principal Investigator System Enables CROs to Improve Bioanalytical Study Management

February 10, 2011 10:26 am | by Richard LeLacheur, Vice President, PharmaNet, Princeton, NJ | Articles | Comments

In order to ensure smooth operation during bioanalytical studies, a novel model, where a principal investigator with direct control over the entire study is the core of the project, has been developed.

TOPICS:

Micro Bioreactor System

February 10, 2011 6:08 am | Product Releases | Comments

The Automation Partnership, a leader in the design and development of innovative automation for life science applications, has announced its micro bioreactor system, ambr, is now available with integrated Beckman Coulter Vi-CELL Cell Viability Analyser.

TOPICS:

Infrared Spectrometer

February 10, 2011 6:02 am | Product Releases | Comments

PerkinElmer Inc. announced the launch of the Frontier Infrared Spectrometer, a high performance infrared (FT-IR) spectrometer built using PerkinElmer’s industry-leading spectroscopy expertise.

TOPICS:
Advertisement

Fluidigm Announces IPO Pricing

February 10, 2011 5:42 am | News | Comments

Fluidigm Corporation announced the pricing of its initial public offering of 5,558,333 shares of its common stock at a price to the public of $13.50 per share. The shares of common stock have been approved to trade on The NASDAQ Global Market under the symbol "FLDM."

TOPICS:

Auxilium Revenue Up, Profit Down

February 10, 2011 5:38 am | News | Comments

Auxilium Pharmaceuticals Inc. said its fourth-quarter loss widened, even though revenue grew 29 percent, as the biopharmaceutical company incurred growing expenses tied to its Dupuytren's contracture treatment Xiaflex.

TOPICS:

Several New Prostate Cancer Genes Detected

February 10, 2011 5:34 am | News | Comments

For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease.

TOPICS:

Firefly Protein Lights Way to Better Heparin Monitoring

February 10, 2011 5:30 am | News | Comments

The enzyme that makes fireflies glow is lighting up the scientific path toward a long-sought new medical imaging agent to better monitor treatment with heparin, the blood thinner that millions of people take to prevent or treat blood clots.

TOPICS:

NHGRI Charts Course for Genomics Research

February 10, 2011 5:22 am | News | Comments

A new strategic plan from an arm of the National Institutes of Health envisions scientists being able to identify genetic bases of most single-gene disorders and gaining new insights into multi-gene disorders in the next decade.

TOPICS:

FDA OKs Generic Duragesic Patch

February 10, 2011 5:18 am | News | Comments

Irish drug maker Covidien PLC said it received Food and Drug Administration approval for a generic version of Johnson & Johnson's Duragesic pain patch. The patch manages persistent, moderate to severe chronic pain in opiod-tolerant patients.

TOPICS:

FDA Halts Idenix AIDS Trial

February 10, 2011 5:16 am | News | Comments

Idenix Pharmaceuticals Inc. revealed that federal regulators have temporarily halted studies of an HIV and AIDS drug that the company developed. Idenix said it was informed by its partner ViiV Healthcare that the FDA placed a clinical hold on studies of the drug.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading